ITGAX and melanoma: TLR7/8 agonist treatment counteracted the increase in NK1.1+CD11c+ cells observed for the melanoma-bearing mice (PBS group), reaching values close to those of the healthy group for both the IMQ and GDQ groups of mice (Figure 8g).